• 1
    Raskind MA, Peskind ER, Holmes C et al. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol. Psychiatry 1999; 46: 756765.
  • 2
    Hoogendijk WJ, Feenstra MG, Botterblom MH et al. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 1999; 45: 8291.
  • 3
    Sheline YI, Miller K, Bardgett ME et al. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction. Am. J. Geriatr. Psychiatry 1998; 6: 155161.
  • 4
    Tohgi H, Ueno M, Abe T et al. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J. Neural. Transm. Park Dis. Dement. Sect. 1992; 4: 6977.
  • 5
    Martignoni E, Blandini F, Petraglia F et al. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural. Transm. Park Dis. Dement. Sect. 1992; 4: 191205.
  • 6
    Liu HC, Yang JC, Chang YF et al. Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease. Ann. N. Y. Acad. Sci. 1991; 640: 215218.
  • 7
    Brane G, Gottfries CG, Blennow K et al. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis. Assoc. Disord. 1989; 3: 148156.
  • 8
    Oonishi M, Mochizuki H, Yoshihashi H et al. Laboratory examinations correlated with severity of dementia. Ann. Clin. Lab. Sci. 1996; 26: 340345.
  • 9
    Storga D, Vrecko K, Birkmayer JG et al. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci. Lett. 1996; 203: 2932.
  • 10
    Gottfries CG. Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology (Berl). 1985; 86: 245252.
  • 11
    Parnetti L, Reboldi GP, Santucci C et al. Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders. Aging (Milano) 1994; 6: 201207.
  • 12
    Azorin JM, Raucoules D, Valli M et al. Plasma levels of 3-methoxy-4-hydroxyphenylglycol in depressed patients compared with normal controls. Neuropsychobiology 1990; 23: 1824.
  • 13
    Karege F, Bovier P, Hilleret H et al. Lack of effect of anxiety on total plasma MHPG in depressed patients. J. Affect. Disord. 1993; 28: 211217.
  • 14
    Muscettola G, Potter WZ, Pickar D et al. Urinary 3-methoxy-4- hydroxyphenylglycol and major affective disorders. A replication and new findings. Arch. Gen. Psychiatry 1984; 41: 337342.
  • 15
    Scatton B, Loo H, Dennis T, Poirier-Littre MF. Decrease in plasma levels of 3,4-dihydroxyphenylethyleneglycol in major depression. Psychopharmacology (Berl) 1986; 88: 220225.
  • 16
    Leckman JF, Maas JW, Redmond DE et al. Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) in men: Preliminary report. Life Sci. 1980; 26: 21792185.
  • 17
    Reuster T, Rilke O, Oehler J. High correlation between salivary MHPG and CSF MHPG. Psychopharmacology (Berl) 2002; 162: 415418.
  • 18
    Yang RK, Yehuda R, Holland DD et al. Relationship between 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers. Biol. Psychiatry 1997; 42: 821826.
  • 19
    Yamada S, Yajima J, Harano M et al. Saliva level of free 3-methoxy-4-hydroxyphenylglycol in psychiatric outpatients with anxiety. Int. Clin. Psychopharmacol. 1998; 13: 213217.
  • 20
    Li GY, Ueki H, Yamamoto Y et al. Association between the scores on the general health questionnaire-28 and the saliva levels of 3-methoxy-4-hydroxyphenylglycol in normal volunteers. Biol. Psychol. 2006; 73: 209211.
  • 21
    Li GY, Ueki H, Kawashima T et al. Involvement of the noradrenergic system in performance on a continuous task requiring effortful attention. Neuropsychobiology 2004; 50: 336340.
  • 22
    Yamada S, Yamauchi K, Yajima J et al. Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders. Psychiatry Res. 2000; 93: 217223.
  • 23
    Nazarali AJ, Reynolds GP. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: A postmortem study. Cell. Mol. Neurobiol. 1992; 12: 581587.
  • 24
    Herregodts P, Bruyland M, De Keyser J et al. Monoaminergic neurotransmitters in Alzheimer's disease: An HPLC study comparing presenile familial and sporadic senile cases. J. Neurol. Sci. 1989; 92: 101116.
  • 25
    Lawlor BA, Bierer LM, Ryan TM et al. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol. Psychiatry 1995; 38: 185188.
  • 26
    Mann DM, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry 1982; 45: 113119.
  • 27
    Ala T, Hughes L, Kyrouac G et al. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2001; 70: 483488.
  • 28
    Schuessel K, Leutner S, Cairns NJ et al. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J. Neural. Transm. 2004; 111: 11671182.
  • 29
    Del Rio G, Velardo A, Zizzo G et al. Effect of estradiol on the sympathoadrenal response to mental stress in normal men. J. Clin. Endocrinol. Metab. 1994; 79: 836840.